Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Contact angle between solid and liquid. by Xinhui Luo (11880086)

“…We prepared the blends of these five surfactants, each with a mass fraction of 0.5 wt%, in a 1:1 ratio, resulting in 10 blended solutions. …”

Diagram of the experimental equipment. by Xinhui Luo (11880086)

“…We prepared the blends of these five surfactants, each with a mass fraction of 0.5 wt%, in a 1:1 ratio, resulting in 10 blended solutions. …”

Sedimentation experimental device. by Xinhui Luo (11880086)

“…We prepared the blends of these five surfactants, each with a mass fraction of 0.5 wt%, in a 1:1 ratio, resulting in 10 blended solutions. …”

The wetting feature of compound solutions. by Xinhui Luo (11880086)

“…We prepared the blends of these five surfactants, each with a mass fraction of 0.5 wt%, in a 1:1 ratio, resulting in 10 blended solutions. …”

Absorption peaks of groups. by Xinhui Luo (11880086)

“…We prepared the blends of these five surfactants, each with a mass fraction of 0.5 wt%, in a 1:1 ratio, resulting in 10 blended solutions. …”

Infrared spectrogram of lignite. by Xinhui Luo (11880086)

“…We prepared the blends of these five surfactants, each with a mass fraction of 0.5 wt%, in a 1:1 ratio, resulting in 10 blended solutions. …”

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

“…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC₅₀ = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

“…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC₅₀ = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”

Trade-offs between suppressing cheaters and decreasing the time to stochastic clearance of a pure producer population, as controlled by <i>K</i>_<i>a</i>, are present for... by Alexander S. Moffett (8250291)

Claudin V is decreased following infection with Mtb. by Amanda S. Latham (12093638)

“…<p>Immunofluorescent staining of guinea pig brain tissue for DAPI (blue) and claudin V (cyan) in vessels was performed. Representative images of the frontal cortex (A–D), cerebral nuclei (F–I), brain stem (K–N), thalamus (P–S), and hippocampus (U–X) 15 days post-infection are shown. …”

Brain uptake rate of [¹⁴C]docosahexaenoic acid (DHA) in the whole brain and each brain region. by Takuro Iwao (14636741)

Subjects:

Brain uptake rate of [¹⁴C]sucrose in the whole brain and individual brain regions. by Takuro Iwao (14636741)

Subjects:

C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

“…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”

C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

“…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”

C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

“…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”